Ceraxon, 100 mg/ml 30 ml

Ceraxone is a nootropic drug.

Cyticolin, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: promotes repair of damaged cell membranes, inhibits phospholipases, preventing excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.

In the acute period of stroke, citicoline reduces the volume of brain tissue damage and improves cholinergic transmission.

In craniocerebral trauma reduces the duration of post-traumatic coma and severity of neurological symptoms, moreover, citicoline helps to reduce the duration of recovery period.

In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. It increases the level of attention and consciousness and reduces the manifestation of amnesia.

Ceraxone® is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Indications

Active ingredient

Composition

1 ml of oral solution contains:

active ingredient:

citicoline sodium (equivalent to 100 mg of citicoline)

excipients:

sorbitol, 200 mg;

glycerol, 50 mg;

methyl parahydroxybenzoate, 1.45 mg;

propylparahydroxybenzoate – 0.25 mg;

sodium citrate dihydrate – 6 mg;

sodium saccharinate – 0.2 mg;

Strawberry flavoring (essence of strawberry 1487-S-Lucta) – 0.408 mg;

Potassium sorbate – 3 mg;

Citric acid 50% solution – to pH 6;

Purified water – to 1 ml

How to take, the dosage

The drug is taken with meals or between meals. Before use, the drug may be diluted in a small amount of water (120 ml or 1/2 cup).

Acute period of ischemic stroke and brain injury: The recommended dose is 1000 mg (10 ml) every 12 hours. The duration of treatment is at least 6 weeks.

The recovery period of ischemic and hemorrhagic strokes, the recovery period of brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg/day. (5-10 ml 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease.

Interaction

Citicoline enhances the effects of levodopa.

Ceraxone® should not be administered concomitantly with drugs containing meclofenoxate.

Special Instructions

During treatment, caution should be exercised when performing potentially hazardous activities requiring special attention and quick reactions (driving a car and other vehicles, working with moving machinery, work of a dispatcher and operator, etc.).

The oral solution (optional). Slight amounts of crystals may form in the cold due to temporary partial crystallization of the preservative. The crystals will dissolve within a few months if stored under the recommended conditions. The presence of crystals does not affect the quality of the product.

Contraindications

Side effects

Very rare (less than 1/10000) (including individual cases): allergic reactions (rash, skin itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, edema, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in liver enzyme activity.

In some cases, Zeraxon® may stimulate the parasympathetic system and also cause transient BP changes.

If any of the side effects listed in the instructions worsen, or if any other side effects not listed in the instructions are noticed, you should tell your doctor.

Overdose

In view of the low toxicity of the drug, no cases of overdose have been described.

Pregnancy use

There are no sufficient data on the use of citicoline in pregnant women.

While no adverse effects have been shown in animal studies, during pregnancy the drug Zeraxon® is prescribed only when the expected benefit to the mother outweighs the potential risk to the fetus.

Women should stop breastfeeding when prescribing Ceraxon® during lactation, because there are no data on citicoline excretion in women’s milk.

Similarities